Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | CD274 over exp |
Gene Variant Detail | |
Relevant Treatment Approaches | PD-L1/PD-1 antibody |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06698042 | Phase III | Pembrolizumab MK-3475A + Pembrolizumab | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | Recruiting | USA | TUR | ROU | POL | ESP | 4 |
NCT06447662 | Phase I | PF-07934040 Gemcitabine + Nab-paclitaxel + PF-07934040 Carboplatin + Pembrolizumab + Pemetrexed Disodium + PF-07934040 Pembrolizumab + PF-07934040 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + PF-07934040 Cetuximab + PF-07934040 Cisplatin + Pembrolizumab + Pemetrexed Disodium + PF-07934040 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | Recruiting | USA | 1 |
NCT04022876 | Phase I | ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | Terminated | USA | POL | ITA | ESP | DEU | 2 |
NCT04613596 | Phase II | Adagrasib + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Adagrasib Carboplatin + Pembrolizumab + Pemetrexed Disodium | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Recruiting | USA | TUR | SWE | ROU | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 18 |
NCT04349280 | Phase I | Bintrafusp alfa | A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer | Terminated | USA | NLD | FRA | ESP | CAN | 0 |
NCT06767514 | Phase III | Pembrolizumab Ivonescimab | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 (HARMONi-7) | Recruiting | USA | 0 |
NCT06119581 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium | A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01) | Recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 7 |
NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |
NCT06084689 | Phase II | BI 907828 + Ezabenlimab | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) | Not yet recruiting | FRA | 0 |
NCT05689671 | FDA approved | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Nab-paclitaxel | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE) | Recruiting | DEU | 0 |
NCT05171777 | Phase II | Atezolizumab | A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer | Completed | USA | POL | LVA | ITA | FIN | ESP | CAN | BRA | ARG | 3 |
NCT06865339 | Phase II | Cemiplimab + Fianlimab | Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (TRIPL) | Not yet recruiting | USA | 0 |
NCT03631706 | Phase II | Bintrafusp alfa Pembrolizumab | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | NLD | ITA | GRC | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 6 |
NCT05840770 | Phase II | Cemiplimab | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05240131 | Phase Ib/II | Atezolizumab + GB1211 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | Active, not recruiting | POL | FRA | ESP | 0 |
NCT04470674 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium Durvalumab | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (>=50%) NSCLC Patients | Withdrawn | USA | 0 |
NCT06170788 | Phase III | Pembrolizumab + SKB264 Pembrolizumab | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >= 50% (MK-2870-007) (TroFuse-007) | Recruiting | USA | TUR | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | AUS | ARG | 11 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Unknown status | AUS | 2 |
NCT05557591 | Phase II | Cemiplimab BNT116 + Cemiplimab | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | Recruiting | USA | TUR | ESP | DEU | 3 |
NCT03801902 | Phase I | Durvalumab + Monalizumab Durvalumab | Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial | Active, not recruiting | USA | 0 |
NCT05383001 | Phase II | Cisplatin + Vinorelbine Carboplatin + Vinorelbine Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Nab-paclitaxel Durvalumab + Tremelimumab Carboplatin + Nab-paclitaxel Cisplatin + Gemcitabine Carboplatin + Gemcitabine | Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) | Withdrawn | DEU | 0 |
NCT04699123 | Phase II | NC318 + Pembrolizumab NC318 | The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05215340 | Phase III | Pembrolizumab Datopotamab deruxtecan + Pembrolizumab | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT05565378 | Phase II | Dostarlimab-gxly Dostarlimab-gxly + EOS-448 Pembrolizumab | A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | Recruiting | USA | TUR | POL | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | BRA | BEL | ARG | 7 |
NCT04274907 | Phase I | Pembrolizumab + Venetoclax Pembrolizumab | A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression | Terminated | USA | 0 |
NCT04966676 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS) | Active, not recruiting | CAN | 0 |
NCT05077709 | Phase II | IO102-IO103 + Pembrolizumab | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | Active, not recruiting | USA | GBR | ESP | 0 |
NCT03308942 | Phase II | Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib | Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | Completed | USA | 0 |
NCT05860296 | Phase Ib/II | Pembrolizumab + SLC-391 | Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | Recruiting | USA | CAN | 0 |
NCT05555732 | Phase III | Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT05144529 | Phase II | Ipilimumab + Nivolumab Evolocumab + Ipilimumab + Nivolumab | A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101) | Recruiting | USA | 0 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Completed | USA | NZL | FRA | ESP | DNK | 1 |
NCT05344209 | Phase II | Atezolizumab Pembrolizumab Cemiplimab Cemiplimab + Sargramostim + UV1 Telomerase peptide vaccine Pembrolizumab + Sargramostim + UV1 Telomerase peptide vaccine Atezolizumab + Sargramostim + UV1 Telomerase peptide vaccine | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC) | Recruiting | NOR | 0 |
NCT06644768 | Phase Ib/II | Pembrolizumab DS-3201b + Pembrolizumab | A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Recruiting | USA | BRA | ARG | 3 |
NCT05937906 | Phase Ib/II | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Mirdametinib + Pembrolizumab + Pemetrexed Disodium | Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. (IMMUNOMEK) | Recruiting | FRA | 0 |
NCT04551521 | Phase II | Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib | CRAFT: The NCT-PMO-1602 Phase II Trial | Completed | DEU | 0 |
NCT04793815 | FDA approved | Pembrolizumab | Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) | Completed | CAN | 0 |
NCT06472076 | Phase III | Pembrolizumab Dostarlimab-gxly + EOS-448 | A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) | Recruiting | TUR | SWE | SVN | SVK | ROU | POL | NLD | ITA | HUN | HRV | GRC | FRA | FIN | EST | ESP | DEU | CZE | CAN | BRA | BGR | BEL | ARG | 12 |
NCT06758401 | Phase III | Pembrolizumab Pembrolizumab + SGN-B6A | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Not yet recruiting | 0 | |
NCT04622007 | Phase II | Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium + Tomivosertib Pembrolizumab Pembrolizumab + Tomivosertib | Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART) | Active, not recruiting | USA | AUS | 1 |
NCT06162572 | Phase Ib/II | Cemiplimab + S095029 Cemiplimab + Sym024 Cemiplimab + Sym023 Cemiplimab | Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | Recruiting | USA | ROU | ITA | HUN | GBR | FRA | ESP | BRA | BEL | AUT | AUS | ARG | 3 |
NCT06345729 | Phase III | Pembrolizumab MK-1084 + Pembrolizumab | A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >=50% (MK-1084-004) | Recruiting | USA | ROU | NZL | NLD | FRA | ESP | CAN | BRA | BGR | AUT | AUS | ARG | 7 |
NCT03228667 | Phase II | Docetaxel + Nivolumab + Nogapendekin alfa inbakicept Docetaxel + Nogapendekin alfa inbakicept + Pembrolizumab Nivolumab + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept + Pembrolizumab Durvalumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Avelumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Atezolizumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Nivolumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Durvalumab + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept + PD-L1.t-haNK cells + Pembrolizumab Avelumab + Nogapendekin alfa inbakicept Atezolizumab + Nogapendekin alfa inbakicept | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | Recruiting | USA | 0 |
NCT06731413 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT06561386 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093) | Recruiting | USA | TUR | ROU | POL | NZL | NLD | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 11 |
NCT05142189 | Phase I | BNT116 + Cemiplimab BNT116 + Docetaxel BNT116 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1) | Recruiting | USA | TUR | POL | HUN | GBR | ESP | DEU | 0 |
NCT04931654 | Phase Ib/II | AZD7789 | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | Active, not recruiting | USA | TUR | NLD | FRA | ESP | CAN | 4 |
NCT05877430 | Phase Ib/II | CJRB-101 + Pembrolizumab | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | Recruiting | USA | 1 |
NCT06099782 | Phase II | MK-3475A Pembrolizumab | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | Active, not recruiting | USA | TUR | POL | NZL | FRA | AUS | ARG | 3 |
NCT06173505 | Phase Ib/II | Carboplatin + Pemetrexed Disodium + XmAb20717 Carboplatin + Pembrolizumab + Pemetrexed Disodium | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Recruiting | USA | POL | NLD | GRC | ESP | BEL | 3 |
NCT06357533 | Phase III | Pembrolizumab AZD2936 + Datopotamab deruxtecan AZD2936 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) | Recruiting | USA | TUR | POL | ITA | HUN | GBR | ESP | DEU | CAN | BRA | BEL | AUT | AUS | 6 |
NCT05609968 | Phase III | Pembrolizumab Pembrolizumab + Sacituzumab govitecan-hziy | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >=50% (MK-3475-D46) | Recruiting | USA | TUR | ROU | POL | LVA | LTU | ITA | ISR | GRC | GBR | EST | DEU | CAN | BRA | AUS | 9 |
NCT03003962 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel | Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | Active, not recruiting | USA | TUR | POL | NLD | HUN | AUS | 6 |
NCT06713798 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures (INDIGO) | Not yet recruiting | FRA | 0 |
NCT04736173 | Phase II | Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (ARC-10) | Active, not recruiting | USA | TUR | GRC | 9 |
NCT04746924 | Phase III | Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | Active, not recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | DEU | BRA | AUS | ARG | 8 |
NCT05785767 | Phase II | Cemiplimab Cemiplimab + Fianlimab | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | TUR | ISR | CAN | AUS | 5 |
NCT04547504 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE) | Active, not recruiting | FRA | 0 |
NCT05879822 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Active, not recruiting | TUR | ROU | NZL | HUN | GRC | BRA | 3 |
NCT05340309 | Phase II | Atezolizumab + rHuPH20 | Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03709147 | Phase II | Carboplatin + Metformin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Metformin + Pembrolizumab + Pemetrexed Disodium | Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME) | Unknown status | ITA | 0 |